Conversely, studies by Barratt et al. [42] and Dalle Fratte et al. [43] reported increased metabolic ratios of NDMI/imatinib in CML and GIST patients carrying the CYP2C8*3 allele, contrasting with our findings. This evidence concerns the gene CYP2C8 and gastrointestinal stromal tumor.